Why was TAOS developed?

The concept of the TAOS (TArgeted, Orchestrated Signalling) technology is founded on the necessity to strike a balance between the commercial need to make regenerative medicine products cost effective and the highly complex process of tissue repair and morphogenesis. The TAOS system is a platform concept that offers precise control over the presentation of microenvironmental cues enabling efficacy and safety enhancements for cell therapies or orchestrating host cell responses to localized repair.

The key clinical features and benefits of the TAOS system include:

  • Presentation of distinct integrin-mediated cues to specify cell adhesion mechanisms.
  • Spatial and temporal control of drug presentation with reduced side-effect profiles.
  • Structural templates reinforce the defect and promote integration with surrounding tissue.
  • Mechanical properties that closely match that of the native tissue.
  • An architecture and geometry (e.g. shape, porosity, pore size) to create a permissive environment for cellular migration, proliferation and differentiation.
  • Biomaterial degradation in a timely manner to facilitate tissue ingrowth.
  • Injectable format to meet the growing need for surgical procedures using minimally invasive techniques.

These clinical attributes make TAOS highly versatile and means that as a technology it offers a platform approach for regenerative surgeries throughout the body.

TAOS

TAOS particle-fused matrices can be used as a regenerative porous tissue scaffold and also creates a versatile drug and cell delivery system.

For further information please email info@locatetherapeutics.com or call +44 (0)115 784 0041.

Product Development Pipeline
Application Development
Partnering Opportunities

© 2014 Locate Therapeutics Limited.

All rights reserved.

Registered in England number 04202562.

Locate Therapeutics Limited

MediCity

Thane Road

Beeston

Nottingham NG90 6BH

United Kingdom

 

+44 (0)115 784 0041

info@locatetherapeutics.com